GLP1R and heart failure: In patients with heart failure who were switched from angiotensin converting enzyme inhibitors or angiotensin receptor blockers to sacubitril/valsartan, a dose-dependent increase of circulating GLP-1 levels has been described, which correlated with a decrease in levels of the protein glycation biomarker fructosamine [30].